Observational studyEuropean journal of pediatrics2026
Visual assessment of bilirubin and transcutaneous bilirubinometry in detecting rebound hyperbilirubinemia requiring phototherapy re-initiation in neonates: a prospective diagnostic accuracy study.
Observational study in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the diagnostic performance of and the potential reduction in blood sampling by (a) visual assessment (VA) for jaundice and (b) transcutaneous bilirubinometry (TcB) at 12-24 h after stopping phototherapy in detecting rebound hyperbilirubinemia requiring re-initiation of phototherapy in neonates born at ≥ 35 weeks' gestation. This prospective observational study was conducted at a tertiary neonatal unit in India. Eligible neonates underwent VA using Modified Kramer's method by a neonatal fellow with > 3 years of pediatrics training, TcB using Dräger JM-105™, and total serum bilirubin (TSB) by point-of-care spectrophotometry (One Beam; Ginevri, Italy) at either 12 h (neonates with hemolytic jaundice) or 24 h (neonates with non-hemolytic jaundice) after phototherapy cessation. Outcomes included sensitivity, specificity, likelihood ratios, and reduction in TSB sampling. Among 160 enrolled neonates (gestation: 36 ± 3 weeks; birthweight: 2743 ± 483 g; 35 [21.9%] with hemolytic jaundice), rebound hyperbilirubinemia occurred in 8 (5%). Sensitivity was 100% for both VA and TcB, with VA demonstrating higher specificity (88.2% vs. 71.7%). Positive predictive values were low (VA: 30.8%; TcB: 15.7%), while negative predictive values were 100% for both. Positive likelihood ratios for VA and TcB were 8.4 and 3.5, respectively. VA and TcB could have reduced TSB sampling in 134 (83.8%; 95%CI 77.0-88.7) and 109 (68.1%; 95%CI 60.4-70.9) neonates, respectively.
conclusionsGiven their excellent sensitivity and negative predictive values, VA and TcB can enable ruling out rebound hyperbilirubinemia after stopping phototherapy. Using them as primary screening tools can significantly reduce the need for blood sampling to detect rebound hyperbilirubinemia. WHAT IS KNOWN: • Rebound hyperbilirubinemia requiring re-initiation of phototherapy occurs in a subset of neonates with pathological hyperbilirubinemia. • While visual assessment (VA) and transcutaneous bilirubinometry (TcB) are non-invasive methods for monitoring jaundice, their role in identifying rebound hyperbilirubinemia remains unclear. WHAT IS NEW: • This study shows excellent sensitivity and negative predictive values of VA and TcB for detecting rebound hyperbilirubinemia. • The results suggest the potential of these two non-invasive methods to decrease blood sampling for serum bilirubin levels, making them valuable tools particularly in resource-constrained settings.
Indexed as
Identifiers
41554989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.